Paclitaxel has been extensively used as an antitumor drug to treat a broad range of epithelial cancers, including breast and cervical cancers. However, the efficacy of this drug is greatly limited by the development of acquired resistance. Identification of the underlying resistance mechanisms may inform the development of new therapies that elicit long-term response of tumors to paclitaxel treatment. Here we report that increased expression of TNFAIP1 (tumor necrosis factor alpha-induced protein 1) confers acquired resistance to paclitaxel. TNFAIP1 is shown to compete with paclitaxel for binding to b-tubulin, thereby preventing paclitaxel-induced tubulin polymerization, cell cycle arrest and ultimate cell death. We also show that expression of TNFAIP1 is regulated by the transcriptional factor Sp1. In a xenograft mouse model, increased expression of TNFAIP1 decreases, whereas knockdown of TNFAIP1 increases tumor response to paclitaxel. Therefore, these results reveal tnfaip1 as a novel paclitaxelresistance associated gene and suggest that TNFAIP1 may represent a valuable therapeutic target for the treatment of cancer.
INTRODUCTION
Paclitaxel was originally isolated from Taxus brevifolia. 1 The subsequent in vitro and in vivo studies have demonstrated that paclitaxel is able to interact with b-tubulin 2,3 and promote tubulin polymerization, 4 ,5 thereby leading to G2/M arrest 6 and the subsequent cell death. 7, 8 Given the potent ability to induce cell cycle arrest and apoptosis, 9, 10 paclitaxel has been widely used in cancer chemotherapy 11, 12 to treat many malignancies, including lung, ovarian, breast, and head and neck cancers. [13] [14] [15] [16] [17] Unfortunately, the efficacy of paclitaxel therapy is greatly limited by the development of paclitaxel resistance. 18, 19 Over the past several decades, tremendous efforts have been directed toward the study of molecular mechanisms of the acquired paclitaxel resistance. Owing to the hydrophobic nature of paclitaxel, acquired resistance to this drug has been associated with the enhanced expression of the multidrug-resistance protein P-glycoprotein-1. 19, 20 As paclitaxel exerts its antitumor function through binding to and stabilizing the polymerized form of microtubules, several studies have focused on determining the changes in different b-tubulin isotype expression 21 or mutations in b-tubulin that impair the paclitaxel-b-tubulin binding in paclitaxelresistant cells. 22 These studies have led to the findings that mutations such as L215H, L215F, A185T, A248V and R306C in the class I b-tubulin are associated with paclitaxel resistance. 23, 24 Moreover, reducing tubulin levels, over-expressing bIII-tubulin or differential expression of specific b-tubulin isotypes also contributes to the development of acquired paclitaxel resistance. 21, [25] [26] [27] More recently, multiple genes including Txr1, GBP1 and KLK7 have been identified as paclitaxel-resistance associated genes through function-based screening and complementary DNA (cDNA) microarray analysis. [28] [29] [30] Given the diversity and complexity of these identified genes associated with paclitaxel resistance, fully defining the underlying mechanisms of resistance is still urgently needed to secure the long-term response of tumor cells to paclitaxel treatment. 31 In order to identify novel mechanism(s) for acquired resistance to paclitaxel, we generated a paclitaxel-resistant cell line TRC30 by chronic exposure of cervical cancer cell line HeLa to paclitaxel. Here we report TNFAIP1 (tumor necrosis factor alpha-induced protein 1) as a novel paclitaxel-resistance associated gene. TNFAIP1 is highly upregulated in paclitaxel-resistant TRC30 cells. Increased expression of TNFAIP1 confers acquired paclitaxel resistance. Mechanistically, TNFAIP1 competes with paclitaxel for binding to b-tubulin, thereby antagonizing paclitaxel-induced tubulin polymerization. We also show that TNFAIP1 expression is controlled by the transcriptional factor Sp1 in response to paclitaxel treatment. Collectively, these data uncover a novel mechanism of paclitaxel resistance in which Sp1-mediated upregulation of TNFAIP1 contributes to acquired resistance to paclitaxel, and suggest that the Sp1-TNFAIP1 axis, particularly TNFAIP1, may represent a novel therapeutic target for the treatment of cancer.
RESULTS

TNFAIP1 confers the resistance of HeLa cells to paclitaxel
In order to identify novel gene(s) that involves in the resistance to paclitaxel, we generated a paclitaxel-resistant cell line by continuous exposure of HeLa cells to 50 nM paclitaxel for 12 days (Supplementary Figure S1A) . This paclitaxel-resistant cell line was referred to as TRC30 hereafter. The paclitaxel-resistance phenotype of TRC30 cell line was confirmed by the soft agar growth assay (Supplementary Figure S1B) and the flow cytometry analysis (Supplementary Figure S1C and S1D). The resistant phenotype of TRC30 was found to be stable after 12 months of continuous culture in medium containing paclitaxel (data not shown).
We next performed cDNA microarray analysis to compare gene expression profiles between HeLa and TRC30 cells. Through this analysis, we found that 15 genes were upregulated and 5 were downregulated in TRC30 cells compared with HeLa cells (Supplementary Figure S1E) . Among these genes, TNFAIP1 was confirmed to be upregulated in TRC30 cells by both real-time reverse transcriptase (RT)-PCR and western blot analyses (Figures 1a and b) .
In order to determine whether increased expression of TNFAIP1 confers the paclitaxel-resistance phenotype of TRC30, we knocked down TNFAIP1 in these cells. This led to a marked increase in the percentage of G2/M phase cells after paclitaxel treatment (Figure 1c ). In addition, compared with control cells, TNFAIP1 knockdown TRC30 showed a decrease in cell viability and an increase in apoptosis in response to paclitaxel treatment ( Figure 1d and Supplementary Figure S1F) . Furthermore, this paclitaxel-induced growth inhibition of TNFAIP1 knockdown TRC30 cells was reversed by ectopic expression of GFP-TNFAIP1 (Figure 1e ). These results indicate that TNFAIP1 contributes to the acquired paclitaxel resistance. We also showed that ectopic expression of TNFAIP1 almost completely reversed paclitaxelinduced G2/M cell cycle arrest (Figure 1f ) and cell viability inhibition (Figure 1g ) in HeLa cells. To further investigate whether Figure S1G) . However, knockdown of TNFAIP1 increased paclitaxel-induced apoptosis in these cells (Supplementary Figure S1H) , indicating the important role of TNFAIP1 in conferring paclitaxel resistance. Taken together, these results demonstrate TNFAIP1 as a novel paclitaxel-resistance associated gene, the upregulation of which contributes to the development of acquired paclitaxel resistance.
TNFAIP1 antagonizes paclitaxel-induced tubulin polymerization We next examined whether TNFAIP1 affects paclitaxel-induced tubulin polymerization. As shown by the soluble (S)/polymerized (P) tubulin fractionation assay, paclitaxel treatment markedly promoted tubulin polymerization in HeLa cells, but not in TRC30 cells (Figure 2a (Figure 2e ). These data indicate that TNFAIP1 inhibits paclitaxel-induced tubulin polymerization. To further confirm this, we investigated the effect of TNFAIP1 on the levels of acetylated a-tubulin, which is an established marker for tubulin stability. 32 The results showed that TNFAIP1 strongly inhibited the ability of paclitaxel to induce a-tubulin acetylation (Figure 2f ). By contrast, knockdown of TNFAIP1 enhanced paclitaxel-induced a-tubulin acetylation in TRC30 cells (Figure 2g ). Furthermore, TNFAIP1 failed to show any effect on demecolcine-induced tubulin depolymerization (Supplementary Figure S2A) . Collectively, these results suggest the specific role of TNFAIP1 in antagonizing paclitaxelinduced tubulin polymerization.
To further determine the effect of TNFAIP1 on paclitaxelinduced tubulin polymerization in vitro, purified recombinant Flag-TNFAIP1 protein was mixed with purified tubulins, paclitaxel and GTP in the indicated combinations (Figure 2h ), followed by measuring the absorbance at 340 nm to monitor tubulin polymer formation. The results showed that paclitaxel-induced polymerization of purified tubulins was greatly inhibited by TNFAIP1 (Figure 2h , blue line vs pink line). Taken together, these results demonstrate that TNFAIP1 inhibits paclitaxel-induced tubulin polymerization.
TNFAIP1-mediated paclitaxel resistance requires its interaction with b-tubulin In order to investigate the underlying mechanism of TNFAIP1-mediated paclitaxel resistance, we sought to examine whether TNFAIP1 interacts with b-tubulin. Using a co-immunoprecipitation assay, the interaction of TNFAIP1 with b-tubulin was readily detected (Figure 3a) . As it has been shown that the region spanning amino acids 249-255 of TNFAIP1 is important for the proliferating cell nuclear antigen (PCNA) interaction, we therefore tested whether this region of TNFAIP1 is also responsible for its binding to b-tubulin. We generated a TNFAIP1 mutant (mut-TNFAIP1), in which all the amino acids 249-255 of wild-type TNFAIP1 were individually altered to alanine (Figure 3b ). In contrast to wild-type TNFAIP1, mut-TNFAIP1 failed to interact with b-tubulin (Figure 3c ), indicating that the region between amino acids 249-255 of TNFAIP1 is responsible for the association with b-tubulin. It is also noteworthy that the interaction between TNFAIP1 and b-tubulin was enhanced following paclitaxel treatment ( Figure 3c , lane 9 vs 10). This enhancing effect of paclitaxel on TNFAIP1-b-tubulin association was also confirmed by an endogenous co-immunoprecipitation assay ( Figure 3d , lane 5 vs 6), which indicates the important physiological function of TNFAIP1 in the development of acquired toxol resistance.
Given the interaction of TNFAIP1 with b-tubulin, we sought to examine whether the b-tubulin-binding ability of TNFAIP1 is essential for preventing paclitaxel-induced tubulin polymerization. We first compared the effects of wild-type TNFAIP1 and mut-TNFAIP1 on tubulin polymer formation induced by paclitaxel. In contrast to wild-type TNFAIP1, mut-TNFAIP1 lost the ability to antagonize paclitaxel-induced tubulin polymerization, as shown by western blot analysis ( Figure 3e ) and immunofluorescence assay (Supplementary Figure S2B) . In addition, unlike wild-type TNFAIP1, mut-TNFAIP1 failed to inhibit paclitaxel-promoted a-tubulin acetylation (Figure 3f ). We next compared the direct effects of TNFAIP1 and mut-TNFAIP1 on paclitaxel-induced tubulin polymerization in vitro. With the increasing amounts of TNFAIP1 added to the in vitro reaction, paclitaxel-induced tubulin polymerization was concurrently decreased. However, mut-TNFAIP1 did not show such an effect (Figures 3g and h ). The subsequent cell cycle distribution analysis by flow cytometry further revealed that wild-type TNFAIP1 effectively prevented paclitaxel-induced G2/M cell cycle arrest, whereas mut-TNFAIP1 did not have a similar effect (Supplementary Figure S2C ). In addition, unlike wild-type TNFAIP1, mut-TNFAIP1 was not able to inhibit paclitaxel-induced cell death (Supplementary Figure S2D) . These combined results suggest that its interaction with b-tubulin is required for TNFAIP1 to confer paclitaxel resistance. . As the region between amino acids 217-231 of b-tubulin has been previously reported as a paclitaxel-binding site, we sought to explore the possibility that TNFAIP1 could compete with paclitaxel for binding to b-tubulin. Purified recombinant Flag-TNFAIP1 or Flag-mut-TNFAIP1 protein was incubated with purified tubulins in the presence of Oregon green fluorescent paclitaxel and GTP at 37 1C for 30 min. After centrifugation, the supernatant was assayed for free Oregon green fluorescent paclitaxel by measuring the absorbance at 488 nm. As shown by this assay, wild-type TNFAIP1, but not mut-TNFAIP1, increased the levels of paclitaxel in the supernatant (Figure 4c ). These data indicate that TNFAIP1 directly inhibits the binding of paclitaxel to polymerized tubulin.
We next performed an in vitro competition assay by using b-tubulin peptide that was identical to the amino acids 217-231 of b-tubulin. b-tubulin peptide was mixed with purified recombinant Flag-TNFAIP1 and purified tubulins in the presence of paclitaxel and GTP as indicated, followed by measuring the absorbance at 340 nm to monitor tubulin polymer formation. The results showed that b-tubulin peptide greatly reversed the inhibitory effect of TNFAIP1 on paclitaxel-induced tubulin polymer formation (Figure 4d ). This was also confirmed by the in vitro sedimentation assay (Figure 4e, lanes 6-9) . Taken together, these results suggest that TNFAIP1 competes with paclitaxel for binding to b-tubulin, and thereby prevents paclitaxel-induced tubulin polymerization.
TNFAIP1 prevents paclitaxel-induced tumor growth inhibition In order to determine the effect of TNFAIP1 on the development of paclitaxel resistance in vivo, we used a xenograft mouse model. HeLa, TRC30 and the other indicated cells were separately injected into the right flank of nude mice. When these xenografts reached TNFAIP1 and paclitaxel resistance Y Zhu et al the similar volume (about 50 mm 3 ), mice were started on treatment with paclitaxel (20 mg/kg) through intraperitoneal injection. Seven days after the commencement of the treatment, the excised tumors were weighed. As shown in Figure 5a , TRC30 xenograft was much larger than HeLa xenograft after paclitaxel treatment. This result further indicates the acquired paclitaxelresistant phenotype of TRC30 cells in vivo. Interestingly, when TNFAIP1 was knocked down in TRC30 cells, treatment with paclitaxel resulted in a much quicker shrinkage of TRC30 xenograft (Figure 5b ). In contrast, shrinkage of GFP-TNFAIP1-expressing HeLa xenograft was much slower than that of GFP-expressing HeLa xenograft after treatment with paclitaxel ( Figure 5c ). However, when TNFAIP1 lost its b-tubulin-binding ability, it failed to show any effect on paclitaxel-induced tumor growth inhibition, as evidenced by the finding that both GFP-expressing HeLa xenograft and GFP-mut-TNFAIP1-expressing HeLa xenograft showed the similar tumor shrinkage rates upon paclitaxel treatment (Figure 5c ). Together, these results suggest that Figure 2 . TNFAIP1 attenuates paclitaxel-induced tubulin polymerization. (a) HeLa and TRC30 cells were treated with 100 nM paclitaxel or DMSO control for 12 h. The soluble (S) and polymerized (P) tubulin fractions were then isolated and subjected to western blot analysis with anti-btubulin antibody. GAPDH was used as a loading control. (b) HeLa cells stably expressing GFP or GFP-TNFAIP1 were treated with or without 100 nM paclitaxel for 12 h. The soluble (S) and polymerized (P) tubulin fractions were then isolated and analyzed by western blot. (c) TRC30 cells expressing either control shRNA or TNFAIP1-1 shRNA were treated with or without 100 nM paclitaxel. Twelve hours after treatment, the soluble (S) and polymerized (P) tubulin fractions were isolated and subjected to western blot analysis. (d) TRC30 cells expressing TNFAIP1-1 shRNA were transfected with either GFP or GFP-TNFAIP1. Twenty-four hours after transfection, cells were treated with or without 100 nM paclitaxel for another 12 h. The soluble (S) and polymerized (P) tubulin fractions were then isolated and subjected to western blot analysis with the indicated antibodies. (e) mCherry-tubulin was transfected into HeLa cells together with either GFP or GFP-TNFAIP1. Twenty-four hours after transfection, cells were treated with or without 100 nM paclitaxel for another 12 h, and then analyzed by a fluorescence microscope. The nuclei were also visualized by Hoechst staining. (f ) HeLa cells were transfected with either GFP or GFP-TNFAIP1. Twenty-four hours after transfection, cells were treated with or without 100 nM paclitaxel for another 12 h. Cell lysates were then subjected to western blot analysis with the indicated antibodies. (g) HeLa or TRC30 cells expressing either control shRNA or TNFAIP1-1 shRNA were treated with or without 100 nM paclitaxel. Twelve hours after treatment, cell lysates were then subjected to western blot analysis with the indicated antibodies. (h) Purified recombinant Flag-TNFAIP1 (8 mM) protein was mixed with purified tubulins (20 mM) in the presence of paclitaxel (5 mM) and GTP (100 nM) in the indicated combinations. Tubulin polymerization was then assayed on the basis of the increase in absorbance at 340 nm over time. The transcriptional factor Sp1 controls TNFAIP1 expression in response to paclitaxel treatment It has been recently shown that TNFAIP1 is subjected to the transcriptional regulation by the transcriptional factor Sp1. 33 We therefore asked whether Sp1 is responsible for the upregulation of TNFAIP1 in TRC30 cells. As shown by real-time RT-PCR and western blot analyses, both mRNA and protein of Sp1 were expressed at higher levels in TRC30 cells than in HeLa cells, which correlated well with the increased expression of TNFAIP1 in TRC30 cells (Figure 6a ). In addition, when Sp1 was knocked down in TRC30 cells, expression levels of TNFAIP1 mRNA and protein were also decreased (Figure 6b ). These data suggest the important role of Sp1 in controlling TNFAIP1 gene expression. or Flag-mut-TNFAIP1 (0, 0.5, 1, 2, 4 and 8 mM) protein was mixed with purified tubulins (20 mM) in the presence of paclitaxel (5 mM) and GTP (100 nM) at 37 1C for 10 min. The mixtures were then centrifuged at 14 000 r.p.m. for 10 min to obtain the polymerized tubulin in the pellet fraction (tubulin P). The polymerized tubulin was resolved by SDS-PAGE followed by Coomassie blue staining. The amounts of tubulin input, Flag-TNFAIP1 and Flag-mut-TNFAIP1 were also analyzed by Coomassie blue staining and western blot. Given the transcriptional regulation of TNFAIP1 by Sp1, we sought to examine whether Sp1 regulates paclitaxel-induced tubulin polymerization via TNFAIP1. As shown by the soluble (S)/ polymerized (P) tubulin fractionation assay, Sp1 knockdown promoted paclitaxel-induced tubulin polymerization in TRC30 cells (Figure 6d , lanes 5 and 6 vs lanes 7 and 8), which recapitulates the effect of TNFAIP1 knockdown (Figure 2c) . However, when GFP-TNFAIP1 was exogenously expressed in HeLa cells, Sp1 knockdown did not show any effect on paclitaxelinduced tubulin polymerization (Figure 6e , lanes 5 and 6 vs lanes 7 and 8). As exogenous TNFAIP1 expression is not affected by Sp1 knockdown, this finding indicates that Sp1 antagonizes paclitaxelinduced tubulin polymer formation via TNFAIP1. Collectively, all these data strongly suggest that the Sp1-TNFAIP1 axis has an important role in the development of paclitaxel resistance.
DISCUSSION
Paclitaxel is a tubulin stabilizing agent that exhibits potent antitumor ability in various human malignancies, including cervical cancer, 3 which is the leading cause of death from gynecological malignancies. Despite significant initial response rates for advanced cervical carcinoma using paclitaxel-based (20 mM) in the presence of paclitaxel (5 mM), GTP (100 nM) and increasing amounts of b-tubulin peptide (0, 2, 4 and 8 mM) at 37 1C for 10 min. The mixtures were then centrifuged at 14 000 r.p.m. for 10 min to obtain the polymerized tubulin in the pellet fraction (tubulin P). The polymerized tubulin was resolved by SDS-PAGE followed by Coomassie blue staining. The amounts of tubulin input and Flag-TNFAIP1 were also analyzed by Coomassie blue staining and western blot, respectively.
TNFAIP1 and paclitaxel resistance Y Zhu et al combination therapy, many patients relapse eventually because of the development of acquired resistance to this drug. 34 Therefore, exploration of the detailed molecular mechanisms of acquired paclitaxel resistance remains warranted. This would facilitate the development of new therapies and identify new biomarkers for predicting resistance. In this study, we have provided evidence that increased expression of TNFAIP1 contributes to the development of acquired paclitaxel resistance.
TNFAIP1, also termed as B12, was originally identified as a tumor necrosis factor alpha (TNFa) and interleukin-6 inducible gene. 35 The subsequent studies have shown that TNFAIP1 is also upregulated in Alzheimer's disease brains and in Hepatitis B virus (HBV)-immunized twin, implicating its potential role in the development of Alzheimer's disease 36 and the innate immunity against HBV. 37 In addition, TNFAIP1 has been shown to directly interact with PCNA via a PCNA-binding motif (QTKV-EFP) at the C terminus, therefore promoting PCNA-dependent pold activity. 38 Although these evidences suggest that TNFAIP1 may be involved in various cellular events, very little is known about the physiological function of TNFAIP1. Our data therefore uncover a novel and unexpected function of TNFAIP1 in association with paclitaxel resistance. In this study, we also provide the detailed mechanism by which TNFAIP1 confers acquired resistance to paclitaxel. TNFAIP1 is shown to compete with paclitaxel for binding to b-tubulin, thereby preventing paclitaxel-induced tubulin polymerization, G2/ M cell cycle arrest and eventual cell demise. The deletion analyses also reveal that the region between amino acids 249-255 of TNFAIP1 is essential for its binding to b-tubulin (Figure 3c ). The direct binding of TNFAIP1 to b-tubulin appears to be indispensible for its anti-paclitaxel activity, as supported by the finding that a mutant TNFAIP1 (mut-TNFAIP1), which is unable to interact with b-tubulin, has no effect on paclitaxel-induced tubulin polymerization ( Figure 3 ). Of note, this b-tubulin-interacting domain of TNFAIP1 has been recently recognized as a critical region for binding to PCNA. 38 Therefore, it is not inconceivable that PCNA may participate in the regulation of microtubule dynamics through TNFAIP1. Despite the recent finding that TNFAIP1 exhibits pro-apoptotic activity, 39 we did not observe obvious apoptotic HeLa cells by TNFAIP1 induction. Instead, ectopic expression of TNFAIP1 strongly prevents paclitaxel-induced tumor growth inhibition in a xenograft mouse model (Figure 5c ).
Intriguingly, we show that expression of TNFAIP1 is downregulated upon paclitaxel treatment in paclitaxel-sensitive HeLa cells (Supplementary Figure S3A) . This result further indicates the intrinsic anti-paclitaxel function of TNFAIP1, and suggests that elimination of TNFAIP1 may be required for the initiation of paclitaxel-induced tubulin polymerization and G2/M cell cycle arrest. Consistent with this idea, ectopic expression of TNFAIP1 in HeLa cells antagonizes the promoting effect of paclitaxel on tubulin polymer formation and G2/M cell cycle arrest (Figure 2 and Supplementary Figure S2) . Nonetheless, in paclitaxel-resistant TRC30 cells, paclitaxel treatment increases rather than decreases TNFAIP1 expression (Supplementary Figure S3A) , which produces more TNFAIP1 for paclitaxel neutralization. Further analyses reveal that Sp1 indeed controls expression of TNFAIP1 in response to paclitaxel treatment. Also, Sp1 is shown to antagonize paclitaxelinduced tubulin polymerization upstream of TNFAIP1 ( Figure 6 ). These results indicate the important function of the Sp1-TNFAIP1 axis in the development of acquired paclitaxel resistance. Because of this, it would be informative to examine the expression levels of Sp1 and TNFAIP1 in paclitaxel-treated clinical tumor samples for the purpose of paclitaxel resistance prediction. In this study, we found that TRC30 cells, but not HeLa cells, exhibited the increased secretion of interleukin-6 and TNFa in response to paclitaxel treatment (Supplementary Figure S4A) , indicating that autocrine interleukin-6 and TNFa signaling may partially contribute to paclitaxel resistance. In support of this finding, knockdown of TNFR1 indeed mildly increased paclitaxel-induced apoptosis of TRC30 cells (Supplementary Figure S4B) .
Taken together, our data uncover a novel mechanism of acquired paclitaxel resistance and suggest that TNFAIP1 may represent a valuable therapeutic target for the treatment of cancer with paclitaxel resistance. However, there are still several issues TNFAIP1 and paclitaxel resistance Y Zhu et al remaining to be addressed. For instance, it would be interesting to know how Sp1 is upregulated in paclitaxel-resistant TRC30 cells upon paclitaxel treatment. This is currently under investigation. In addition, as increased expression of TNFAIP1 confers acquired resistance of HeLa cells to paclitaxel, it would be important to address whether TNFAIP1 is indeed upregulated in the clinical post-relapsed tumor samples after paclitaxel treatment. However, it is not feasible to collect the post-relapsed tumor samples for this investigation owing to the fact that surgical resection is rarely performed for resistant/refractory tumors, especially for breast cancer patients. Therefore, we used a xenograft mouse model to address whether TNFAIP1 contributes to paclitaxel resistance in vivo. We show that shrinkage of GFP-TNFAIP1-expressing HeLa xenograft is indeed much slower than that of GFP-expressing HeLa xenograft after treatment with paclitaxel ( Figure 5c ). We also analyzed the expression levels of TNFAIP1 in 26 human primary breast cancers. Eighteen of 26 breast cancers exhibited relatively low levels of TNFAIP1 expression (Supplementary Figure S4C) . This result indicates that low expression of TNFAIP1 may correlate with the high response rate of breast cancers to paclitaxel treatment. In summary, we report tnfaip1 as a novel paclitaxel-resistance associated gene, whose upregulation contributes to acquired paclitaxel resistance.
MATERIALS AND METHODS
Cell culture and transfection
The paclitaxel-resistant TRC30 cell line was obtained by continuously maintaining HeLa cells in a medium containing 50 nM paclitaxel for 12 days. HeLa and TRC cell lines were cultured in DMEM medium supplemented with 10% heat-inactivated fetal bovine serum, 1 Â nonessential amino acid, 100 mg/ml penicillin, 1 Â MEM sodium pyruvate and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 1C under an atmosphere of 5% CO 2 in air. Transient transfection was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Antibodies and reagents
The following antibodies and reagents were obtained from the indicated sources: antibodies against b-tubulin (Cell Signaling, Danvers, MA, USA, no. 2146), TNFAIP1 (Abmart, Shanghai, China), FLAG (Sigma), GFP (Sigma, St Louis, MO, USA), AC-a-tubulin (Abcam), Sp1 (Santa Cruz, Santa Cruz, CA, USA, sc-17824) and GAPDH (Cell Signaling, no. 2118s ); Sp1 siRNA (Santa Cruz, sc-29487); tubulin porcine (Sigma, T6954); paclitaxel for cell culture experiments (Sigma, T7191); paclitaxel for intraperitoneal injection (Kayon, Shanghai, China); Oregon green fluorescent paclitaxel (Molecular Probes, Carlsbad, CA, USA); Annexin V-FITC/PI (SAB CA001).
RNA interference
To inhibit SP1 expression in HeLa cells, SP1-specific siRNA (Santa Cruz, sc-29487) was transfected into HeLa cells with Oligofectamine (Invitrogen) according to the manufacturer's instructions.
To knock down TNFAIP1 expression, we obtained the pcDNATM 6.2-GW/ EmGFP-miR-based plasmids expressing control or TNFAIP1 small hairpin RNA (shRNA) from Invitrogen Corporation. Cells were transfected with these plasmids. Twenty-four hours after transfection, cells were selected with 2 mg/ml blasticicidin. The cell clones stably expressing control or TNFAIP1 shRNA were isolated and expanded for further analysis. The oligo sequences used for construction of the plasmid expressing TNFAIP1 shRNA were as follows: shRNA TNFAIP1-1, 5
0 -TGCTGAATACTTTGCTTCAGCCAT CAGTTTTGGCCACTGACTGACTGATGGCTAGCAAAGTATT-3 0 (forward) and 5 0 -CCTGAATACTTTGCTAGCCATCAGTCAGTCAGTGGCCAAAACTGATGGCT GAAGCAAAGTATTC-3 0 (reverse); shRNA TNFAIP1-2 5 0 -TGCTGTAGAGTAG GACGTTGAGTGTCGTTTTGGCCACTGACTGACGACACTCAGTCCTACTCTA-3 0 (forward) and 5 0 -CCTGTAGAGTAGGACTGAGTGTCGTCAGTCAGTGGCCAAA ACGACACTCAACGTCCTACTCTAC-3 0 (reverse). We also constructed PLKO.1-based plasmids to express TNFAIP1 or TNFR1 shRNA. The oligo sequences used for construction of the plasmid expressing TNFAIP1 shRNA were as follows: shRNA TNFAIP1-3, 5 0 -CCGGGCAACAAGTATGTCCAGCTCACTCGAGTGAGCTGGACATACTTGTTG CTTTTTTG-3 0 and shRNA TNFAIP1-4, 5 0 -CCGGCGTGCTCTTCATCAAGGA Western blot analysis and co-immunoprecipitation
Western blot analysis was performed as previously described. 40 For co-immunoprecipitation, cells were lysed in immunoprecipitation (IP) lysis buffer (0.5% NP-40, 150 mM NaCl, 20 mM HEPES, pH 7.4, 2 mM EDTA and 1.5 mM MgCl 2 ) supplemented with 1 Â protease inhibitor cocktail (Roche, Basel, Switzerland) for 1 h on ice. Cell lysates were incubated with protein A/G-sepharose beads coated with the indicated antibodies at 4 1C for 4 h. The immunoprecipitates were washed five times with IP lysis buffer and resolved by SDS-PAGE followed by western blot analysis.
Chromatin immunoprecipitation
HeLa or TRC30 cells were transfected with control siRNA or SP1 siRNA. Twenty-four hours after transfection, cells were treated with or without 100 nM paclitaxel for another 12 h. Cells were fixed with 1% formaldehyde and then sonicated to obtain soluble chromatin. After dilution, the chromatin solutions were incubated with protein A/G-sepharose beads coated with anti-SP1 antibody or an isotype-matched control immunoglobulin G. After extensive washing of the beads, the bound DNA fragments were eluted and subjected to PCR amplification with the following primer pairs: TNFAIP1, 5 0 -ggtacccagccagcctgcac-3 0 and 5 0 -tctcagctgggtggccagc-3 0 ; b-actin, 5 0 -gacctgactgactcactcatgaagat-3 0 and 5 0 -gtcacacttcatgatggagtt gaagg-3 0 .
Cell cycle analysis
Cells grown on a six-well plate were treated with or without 100 nM paclitaxel. Twelve hours after treatment, cells were harvested and fixed in 70% ethanol for 3 h at 4 1C. Analysis of cell cycle by flow cytometry was performed as previously described. 41 MTT assay
Cells were seeded in 96-well plates and treated with paclitaxel for the indicated periods of time. Twenty microliters of 5 mg/ml MTT stock solution was added to each well followed by incubation at 37 1C for 4 h. The cells were then incubated with DMSO for 10 min at 37 1C. The absorbance at 570 nm was recorded by a microplate reader.
Soluble/polymerized tubulin fractionation Soluble and polymerized tubulin fractionation was mainly performed as previously described. 42 Briefly, cells were lysed in PEM buffer (80 mM PIPES pH 6.9, 2 mM EGTA, 1 mM MgCl 2 , 0.05% Triton X-100) supplemented with 1 Â cocktail (Roche) at 37 1C for 1 h. After spinning at 3000 r.p.m. for 10 min, the supernatant fraction containing soluble tubulin and the pellet fraction containing polymerized tubulin were directly boiled in the SDS-PAGE sample buffer and subsequently analyzed by western blot.
In vitro tubulin polymerization assay
In order to purify recombinant TNFAIP1 protein, Flag-TNFAIP1 was transfected into HEK 293T cells. Twenty-four hours after transfection, cell lysates were immunoprecipitated with anti-Flag M2 affinity beads (Sigma). The beads were washed extensively by sequential washes with IP lysis buffer containing 0.25, 0.5 and 1 M KCl to remove the nonspecific-binding proteins. Proteins were then eluted from beads with 3 Â Flag peptide TNFAIP1 and paclitaxel resistance Y Zhu et al (Sigma). The eluted protein concentration was determined by a BCA assay kit (Pierce, Rockford, IL, USA). Purified Flag-TNFAIP1 protein was incubated with purified tubulins (Sigma) in tubulin assembly buffer (80 mM Pipes(pH 6.8), 0.5 mM EGTA, 2 mM MgCl 2 , 100 nM GTP, 100 nM ATP and 10% glycerol) containing 10 mM paclitaxel. The absorbance at 340 nm was immediately recorded over time on a microplate reader to determine tubulin polymerization. Tubulin polymerization was also monitored by Coomassie blue staining. This time, the mixture was incubated at 37 1C for 10 min followed by centrifugation at 16 000 g for another 10 min. The pellet fraction containing polymerized tubulin was resolved by SDS-PAGE and analyzed by Coomassie blue staining.
